RE:RE:The call & mid afternoon update this was taken from oncy's press release:
"Oncolytics expects to finalize the definitive agreements within the next 90 days and open the Precision Promise investigational treatment of pelareorep, checkpoint inhibitor, gemcitabine, and nab-paclitaxel in early 2024."
no mention was made that inclusion in precision promise came late in the game. it was clearly stated there was a 90 day timeframe to finalize the agreement.
the only thing which came "late in the game" seems to be the additonal $5 million grant. but that was for an additional study and wouldn't seem to have been anything which would have held up the "original" agreement finalization.
guess one could say that H1 2024 is early '24 since H2 in comparison would be late '24.
"late in the game" sounds like a red herring and something IS fishy.
can't think of any real reason matt et al could not have said SOMETHING about the agreement timetable since it is an obvious prerequisite to the trial.